



## **Cardiac Transthyretin Amyloid (ATTR) Fellowship Competitive Grant Program - Request for Proposals (RFP)**

### **Introduction**

The International Society of Amyloidosis (ISA) and Pfizer are collaborating to offer a new competitive grant opportunity focused on supporting fellowships in Cardiac Transthyretin Amyloid (ATTR).

The mission of the International Society of Amyloidosis (ISA) is to promote research, education, clinical studies (including diagnosis and treatment), conferences and symposia on all aspects of amyloidosis worldwide.

The mission of Pfizer Global Medical Grants is to accelerate the translation of science into quality patient care through independent grants, partnerships, and collaborations. Pfizer Global Medical Grants supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

The goal of this program is to train physicians to recognize and diagnose cardiac ATTR amyloidosis.

Unlike previous Cardiac Transthyretin Amyloid (ATTR) fellowships, the 2023-2024 fellowships will be structured to support experienced amyloidosis centers in hosting fellows from regions around the globe where a high level of expertise in cardiac amyloidosis is lacking. Fellows are expected to return to their home institutions to provide expertise and mentoring on cardiac ATTR amyloidosis in their regions.

This Request for Proposals (RFP) is being issued by both organizations. An expert review panel selected by ISA will make decisions on which proposals receive funding. Grant funding will be provided directly by Pfizer.

You **must** complete and upload a proposal template as part of your application. [Click here](#) to access the template. See **How to Apply** section below for further instructions.

Through this RFP, Host Institutions will be identified to be paired with a Fellow for the **2023-2024 fellowship year**. Once Host Institutions are identified, ISA will post a Request for Applications (RFA) to identify interested Fellows. The ISA will then select the Fellows and pair each one with a Host Institution.

#### Each Host Institution will be responsible for:

- Guidance to fellow on housing options
- Advancing salary (or arrangements) for housing deposit
- Onboarding and orientation for fellow
- Providing a primary and a secondary mentor for fellow
- Arranging fellow's schedule
- Providing or approving information and photos for ISA's efforts to report on/promote fellowship
- Completing survey/evaluation of program at 12 months.

ISA will cover the cost of fellows' round-trip travel to the Host Institutions up to US \$2,000 per fellow. Each fellow will be responsible for housing, food and (if not provided by the Host Institution) health insurance.

## Competitive Grant Program Eligibility

<b>Geographic Scope</b>	Global
<b>Applicant Eligibility Criteria</b>	<p>To be eligible:</p> <ul style="list-style-type: none"> <li>• Do <u>not</u> include the name of the potential fellow(s) in application materials. This grant will be awarded to an institution, not an individual.</li> <li>• Institution's amyloidosis center or program must have specialists with expertise in diagnosing and treating AL amyloidosis (hematologists) and cardiac amyloidosis (cardiologists and individuals with expertise in advanced cardiac imaging--scintigraphy, MRI, and echocardiography). Expertise in at least 2 additional disciplines from the following list is required: neurology, pathology, nephrology, and organ transplantation. Where possible, clinical experience in managing advanced heart failure and organ transplantation should be included.</li> <li>• Institution's amyloidosis program must have a volume of patients such that a fellow would see a mix of types of amyloidosis and at least 15 patients with amyloidosis per week (new and follow-up on an outpatient basis)</li> <li>• The Institution should have the ability to provide at least two mentors (a primary and a secondary, both should be ISA members) who can meet with fellow at least twice per month and guide the fellow towards achieving his/her developmental objectives</li> <li>• Centers or programs should have a track record of clinical trials, research, and publications</li> <li>• Centers or programs must propose an educational curriculum, which may include attending regional or national conferences.</li> <li>• Fellow time spent in the clinical setting that is supported through grant funds must not be billed as patient care.</li> <li>• No aspect of the fellowship program can benefit Pfizer's business or a Pfizer asset.</li> </ul>

## Requirements

<b>Date RFP Issued</b>	2 December 2022
<b>Clinical Area</b>	Cardiac Transthyretin Amyloid (ATTR).
<b>Area of Interest Focus</b>	<ul style="list-style-type: none"> <li>• This is a program based (not project based) grant to identify Host Institutions for Cardiac Transthyretin Amyloid Fellows</li> <li>• It is our intent to support institutions with fellowship programs for Cardiologists that have a strong focus on clinical practice, research, and education to further the understanding of Cardiac Transthyretin Amyloid (ATTR).</li> <li>• The selected Host Institutions will be paired with a Fellow selected by the ISA.</li> </ul>

<p><b>Expected Approximate Monetary Range of Grant Applications</b></p>	<ul style="list-style-type: none"> <li>• Grant funding is available to support one fellow for a year at <b>up to \$125,000</b>. The budget <b>may only include salary and support of the fellow benefits</b>.</li> <li>• Grant funds cannot be used for overhead or indirect costs.</li> <li>• Funding will be awarded to the institution, not an individual.</li> <li>• Fellow time spent in the clinical setting that is supported through grant funds must not be billed as patient care.</li> <li>• No aspect of the fellowship program budget can reflect a benefit to Pfizer's business or a Pfizer asset.</li> </ul>
<p><b>Key Dates</b></p>	<ul style="list-style-type: none"> <li>• RFP release date: 2 December 2022</li> <li>• Full Proposal Deadline: 5 January 2023</li> <li>• Review of Full Proposals by Expert Review Panel: January 2023</li> <li>• Anticipated Full Proposal Notification Date: January/February 2023</li> <li>• Grants distributed in 2023 following execution of fully signed Contract</li> </ul>
<p><b>How to Apply</b></p>	<ul style="list-style-type: none"> <li>• Please go to <a href="http://www.cybergrants.com/pfizer/GMGFellowship">http://www.cybergrants.com/pfizer/GMGFellowship</a> and sign in. First-time users should click "Create your password".</li> <li>• Select the following Competitive Grant Program Name: <b>2023 RD G – ISA Global ATTR Fellowship</b></li> <li>• Requirements for submission: <ul style="list-style-type: none"> <li>○ Complete all required sections of the online application</li> <li>○ <b>You must upload a Proposal Template. <a href="#">Click here to access the template for the Proposal.</a></b></li> </ul> </li> <li>• If you encounter any technical difficulties with the website, please click the "Technical Questions" link at the bottom of the page.</li> </ul>
<p><b>Questions:</b></p>	<ul style="list-style-type: none"> <li>• If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Amanda Stein (<a href="mailto:amanda.j.stein@pfizer.com">amanda.j.stein@pfizer.com</a>), with the subject line "2023 RD G – ISA Global ATTR Fellowship"</li> <li>• Please click <a href="#">here</a> to view Frequently Asked Questions regarding the Competitive Grant Program</li> </ul>
<p><b>Review and Approval Process</b></p>	<ul style="list-style-type: none"> <li>• A specific grant program RFP uses an expert review panel (ERP) to make final grant decisions.</li> <li>• The panel will be selected by ISA and will be comprised of professionals from the medical community with advanced degrees and expertise in cardiac ATTR amyloidosis.</li> </ul>

**Mechanism by which Applicants will be Notified:**

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.